Expanding anti-CD38 immunotherapy for lymphoid malignancies.
All-trans retinoic acid
CAR T
CD38
Daratumumab
Multiple myeloma
Non-Hodgkin lymphoma
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
28 Jun 2022
28 Jun 2022
Historique:
received:
08
02
2022
accepted:
11
04
2022
entrez:
28
6
2022
pubmed:
29
6
2022
medline:
1
7
2022
Statut:
epublish
Résumé
Lymphoid neoplasms, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and NK/T cell neoplasms, are a major cause of blood cancer morbidity and mortality. CD38 (cyclic ADP ribose hydrolase) is a transmembrane glycoprotein expressed on the surface of plasma cells and MM cells. The high expression of CD38 across MM and other lymphoid malignancies and its restricted expression in normal tissues make CD38 an attractive target for immunotherapy. CD38-targeting antibodies, like daratumumab, have been approved for the treatment of MM and tested against lymphoma and leukemia in multiple clinical trials. We generated chimeric antigen receptor (CAR) T cells targeting CD38 and tested its cytotoxicity against multiple CD38 CD38-CAR T cells dramatically inhibited the growth of CD38 These findings may expand anti-CD38 immunotherapy to a broad spectrum of lymphoid malignancies and call for the incorporation of ATRA into daratumumab or other anti-CD38 immunological agents for cancer therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Lymphoid neoplasms, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and NK/T cell neoplasms, are a major cause of blood cancer morbidity and mortality. CD38 (cyclic ADP ribose hydrolase) is a transmembrane glycoprotein expressed on the surface of plasma cells and MM cells. The high expression of CD38 across MM and other lymphoid malignancies and its restricted expression in normal tissues make CD38 an attractive target for immunotherapy. CD38-targeting antibodies, like daratumumab, have been approved for the treatment of MM and tested against lymphoma and leukemia in multiple clinical trials.
METHODS
METHODS
We generated chimeric antigen receptor (CAR) T cells targeting CD38 and tested its cytotoxicity against multiple CD38
RESULTS
RESULTS
CD38-CAR T cells dramatically inhibited the growth of CD38
CONCLUSIONS
CONCLUSIONS
These findings may expand anti-CD38 immunotherapy to a broad spectrum of lymphoid malignancies and call for the incorporation of ATRA into daratumumab or other anti-CD38 immunological agents for cancer therapy.
Identifiants
pubmed: 35765110
doi: 10.1186/s13046-022-02421-2
pii: 10.1186/s13046-022-02421-2
pmc: PMC9237984
doi:
Substances chimiques
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
210Subventions
Organisme : Cancer Prevention and Research Institute of Texas
ID : RR190043
Informations de copyright
© 2022. The Author(s).
Références
Oncologist. 2008 Feb;13(2):126-38
pubmed: 18305057
N Engl J Med. 2016 Oct 13;375(15):1501-1502
pubmed: 27732828
Int J Hematol. 2009 Apr;89(3):400-402
pubmed: 19330555
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35
pubmed: 15044693
Leuk Lymphoma. 2011 Dec;52(12):2372-9
pubmed: 21740303
Nat Rev Clin Oncol. 2016 Jun;13(6):370-83
pubmed: 27000958
Oncogenesis. 2020 Aug 13;9(8):72
pubmed: 32792499
Expert Opin Investig Drugs. 2014 Apr;23(4):445-52
pubmed: 24555809
Immunity. 1997 Sep;7(3):315-24
pubmed: 9324352
Semin Oncol. 2002 Jun;29(3 Suppl 8):30-9
pubmed: 12082652
Blood Adv. 2021 Dec 14;5(23):5128-5139
pubmed: 34625791
J Immunol. 2005 Mar 1;174(5):2687-95
pubmed: 15728476
Leuk Res. 2013 Aug;37(8):956-62
pubmed: 23587524
J Immunother. 2009 Sep;32(7):689-702
pubmed: 19561539
Am J Clin Pathol. 2005 Sep;124(3):414-20
pubmed: 16191510
Oncologist. 2017 Nov;22(11):1347-1353
pubmed: 28904172
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Blood. 2018 Mar 1;131(9):995-999
pubmed: 29305553
Ann Hematol. 2015 Aug;94(8):1381-8
pubmed: 25865943
Leukemia. 2004 Apr;18(4):763-70
pubmed: 14961041
Blood. 2011 Nov 3;118(18):4817-28
pubmed: 21849486
Front Immunol. 2018 Sep 20;9:2134
pubmed: 30294326
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Front Immunol. 2018 Nov 28;9:2722
pubmed: 30546360
Blood. 2021 Mar 25;137(12):1615-1627
pubmed: 33025009
Blood. 2018 Jan 4;131(1):13-29
pubmed: 29118010
N Engl J Med. 1997 Oct 9;337(15):1021-8
pubmed: 9321529
Mol Ther. 2017 Aug 2;25(8):1946-1958
pubmed: 28506593
Br J Haematol. 2007 Apr;137(2):117-24
pubmed: 17391491
Clin Lymphoma Myeloma Leuk. 2019 May;19(5):275-284
pubmed: 30795996
Haematologica. 2019 Mar;104(3):e100-e103
pubmed: 30190344
Am J Clin Pathol. 2004 Apr;121(4):482-8
pubmed: 15080299
Haematologica. 2016 May;101(5):616-25
pubmed: 26858358
J Transl Med. 2012 Feb 13;10:29
pubmed: 22330761
Cancer Discov. 2018 Sep;8(9):1156-1175
pubmed: 30012853
Oncoimmunology. 2016 Aug 5;5(11):e1217374
pubmed: 27999737
Oncotarget. 2020 Mar 24;11(12):1017-1036
pubmed: 32256976
Leukemia. 2015 Oct;29(10):2039-49
pubmed: 25975191
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958